25 July 2022 - - Germany-based diagnostic technology developer Lifespin GmbH has entered into a scientific collaborative agreement with Biobank Graz and the Clinical Division of Oncology of the Medical University of Graz (Austria) to expand its proprietary database of metabolic human health profiles in the field of oncology, the company said.

Under the agreement, Lifespin will be able to analyze and capture the metabolic profiles from more than 25,000 longitudinal human blood samples involving approximately 4,800 oncological patients.

Terms of the agreement were not disclosed.

Lifespin GmbH is a deep data company that is mapping the metabolic profiles of human health.

The company said it is developing an automated, highly scalable, and cost-effective next generation health diagnostics platform that utilizes artificial intelligence and machine learning to quantitatively identify variations in a person's metabolism from the healthy baseline of relevant peer groups in its database.

These variations can be linked to diseases with high sensitivity and specificity. Lifespin combines biology, deep data, artificial intelligence, and cloud technologies to enable digital metabolic insights for precision diagnostics and personalized disease management.

Earlier this year, to advance its research and development opportunities, and in preparation of its market entry, Lifespin GmbH announced the establishment of a US subsidiary, Lifespin, Inc., based in Boston, Massachusetts.

Commercial products in the regulated space will be software algorithms for health testing, scalable via the cloud as Software-as-a-Service.

Development efforts are ongoing for a suite of products in the field of oncology to further extend Lifespin's product portfolio over the coming years to be made available to participating providers and laboratories.

Lifespin is a deep data company that maps human health based on snapshots of metabolic states. Lifespin has standardized the baseline for human health to detect distinct deviations in the human metabolism caused by diseases.

Studies show that pathogenesis impacts metabolism, causing specific changes in the presence and quantity of metabolites.

Lifespin is building an in-house biobank that already consists of more than 200,000 human blood samples.

Lifespin's proprietary diagnostic technology platform can quantitatively capture individual metabolisms, i.e., up to hundreds of metabolite concentrations with a single Nuclear Magnetic Resonance measurement.

Utilizing its proprietary technology, Lifespin is performing quantitative in-house measurements of metabolomes, digitizing metabolic profiles that include billions of metabolic relationships.

These digital metabolic profiles allow systematic mapping across various health conditions and will enable differential diagnosis and early detection of health conditions, staging of diseases, monitoring of treatment success and personalized medicine.

Lifespin's first regulatory approved Software-as-IVD will be for the early differential diagnosis of Multiple Sclerosis and is expected in Europe in 2022, and thereafter in the United States.

Additional tests for the detection of neurological, cancer, and inflammatory diseases are in the pipeline.

Lifespin's cloud-based business model is built on its proprietary Software-as-a-Service platform for diagnostics and health information and is globally scalable.

Lifespin's advisory board consists of key opinion leaders such as James Rothman (Nobel Laureate in Physiology/Medicine, Sterling Professor of Cell Biology, Yale University, New Haven, CT USA) and other prominent leaders in the relevant fields of study.

Biobank Graz is one of the largest clinical biobanks in the world. Around 20m individual specimens of body fluids and human tissue are stored here.

Biobank Graz allows restricted access to these specimens and associated data for scientific research purposes and projects that have received an approval by the local ethics commission and the legal department.